Exciting new advances in neuro-oncology: The avenue to a cure for malignant glioma

CA Cancer Journal for Clinicians

Volumn 60, Issue 3, 2010, Pages 166-193

  van Meir, Erwin G ^a   Hadjipanayis, Costas G ^a   Norden, Andrew D ^b   Shu, Hui Kuo ^a   Wen, Patrick Y ^b   Olson, Jeffrey J ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFLIBERCEPT; AMG 102; BEVACIZUMAB; BRIVANIB; BRIVANIB ALANINATE; CEDIRANIB; CETUXIMAB; CILENGITIDE; DASATINIB; ENZASTAURIN; ERLOTINIB; EVEROLIMUS; GEFITINIB; IMATINIB; LAPATINIB; LONAFARNIB; LY 31761; N [4 (3 CHLORO 4 FLUOROANILINO) 7 (TETRAHYDRO 3 FURYLOXY) 6 QUINAZOLINYL] 4 DIMETHYLAMINO 2 BUTENAMIDE; NIMOTUZUMAB; PANOBINOSTAT; PF 299804; RAPAMYCIN; TANDUTINIB; TANESPIMYCIN; TEMOZOLOMIDE; TEMSIROLIMUS; TIPIFARNIB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALPROIC ACID; VORINOSTAT; XL 184; XL 765; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR; TUMOR MARKER; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR;

ANTIANGIOGENIC ACTIVITY; APOPTOSIS; ARTICLE; BRAIN HEMORRHAGE; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CANCER GRADING; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RESISTANCE; CANCER STEM CELL; CANCER SURVIVAL; CARCINOGENESIS; CLINICAL PRACTICE; CLINICAL TRIAL; DIARRHEA; DRUG EFFICACY; DRUG TARGETING; DRUG TOLERABILITY; FATIGUE; FLUORESCENCE; GENE EXPRESSION; GLIOBLASTOMA; HUMAN; HYPERTENSION; IMMUNE SYSTEM; MOLECULAR GENETICS; MORBIDITY; NEURAL STEM CELL; NEUROENDOSCOPY; NEUROSURGERY; PHENOTYPE; PRIORITY JOURNAL; PROTEINURIA; RADIATION DOSE; RADIATION SICKNESS; SIGNAL TRANSDUCTION; SURGICAL TECHNIQUE; THROMBOEMBOLISM; WOUND HEALING IMPAIRMENT; BRAIN TUMOR; DRUG ANTAGONISM; DRUG EFFECT; GENETICS; MOLECULAR BIOLOGY; PATHOLOGY; REVIEW; TREATMENT FAILURE;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BRAIN NEOPLASMS; EPIDERMAL GROWTH FACTOR; GLIOBLASTOMA; HUMANS; MOLECULAR BIOLOGY; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; SIGNAL TRANSDUCTION; TREATMENT FAILURE; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 77952555038     PISSN: 00079235     EISSN: 15424863     Source Type: Journal    
DOI: 10.3322/caac.20069     Document Type: Article

References (132)

1. Stieber VW, Mehta MP. Advances in radiation therapy for brain tumors. Neurol Clin. 2007;25:1005-1033.
2. Westphal M, Hilt DC, Bortey E, et al. A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro Oncol. 2003;5:79-88.
3. Brem H, Piantadosi S, Burger PC, et al. Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-brain Tumor Treatment Group. Lancet. 1995;345:1008-1012.
4. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987-996.
5. Norden AD, Young GS, Setayesh K, et al. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology. 2008;70:779-787.
6. Noda SE, El-Jawahri A, Patel D, Lautenschlaeger T, Siedow M, Chakravarti A. Molecular advances of brain tumors in radiation oncology. Semin Radiat Oncol. 2009;19:171-178.
7. Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005;352:997-1003.
8. Paez-Ribes M, Allen E, Hudock J, et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell. 2009;15:220-231.
9. Tuettenberg J, Grobholz R, Seiz M, et al. Recurrence pattern in glioblastoma multiforme patients treated with anti-angiogenic chemotherapy. J Cancer Res Clin Oncol. 2009;135:1239-1244.
10. Carson KA, Grossman SA, Fisher JD, Shaw EG. Prognostic factors for survival in adult patients with recurrent glioma enrolled onto the new approaches to brain tumor therapy CNS consortium phase I and II clinical trials. J Clin Oncol. 2007;25: 2601-2606.
11. Sulman EP, Guerrero M, Aldape K. Transcription profiling of brain tumors: tumor biology and treatment stratification. In: Van Meir EG, ed. CNS Cancer: Models, Markers, Prognostic Factors, Targets and TherapeuticApproaches.1sted.NewYork: Humana Press (Springer); 2009:529-552.
12. Schneider BP, Radovich M, Miller KD. The role of vascular endothelial growth factor genetic variability in cancer. Clin Cancer Res. 2009;15:5297-5302.
13. The Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature. 2008;455: 1061-1068.
14. Hadjipanayis CG, Van Meir EG. Brain cancer propagating cells: biology, genetics and targeted therapies. Trends Mol Med. 2009;14:519-530.
15. Hadjipanayis CG, Van Meir EG. Tumor initiating cells in malignant gliomas: biology and implications for therapy. J Mol Med. 2009;87:363-374.
16. Bachoo RM, Maher EA, Ligon KL, et al. EpidermalgrowthfactorreceptorandInk4a/ Arf: convergent mechanisms governing terminal differentiation and transformation along the neural stem cell to astrocyte axis. Cancer Cell. 2002;1:269-277.
17. Brat DJ, Van Meir EG. Vaso-occlusive and prothrombotic mechanisms associated with tumor hypoxia, necrosis, and accelerated growth in glioblastoma. Lab Invest. 2004;84:397-405.
18. Libermann TA, Nusbaum HR, Razon N, et al. Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin. Nature. 1985;313:144-147.
19. James CD, Carlbom E, Nordenskjold M, Collins VP, Cavenee WK. Mitotic recombination of chromosome 17 in astrocytomas. Proc Natl Acad Sc i U S A. 1989;86:2858-2862.
20. Yin S, Van Meir EG. p53 pathway alterations in brain tumors. In: Van Meir EG, ed. CNS Cancer: Models, Markers, Prognostic Factors, Targets and Therapeutic Approaches. 1st ed. New York: Humana Press (Springer); 2009:283-314.
21. Stokoe D, Furnari FB. The PTEN/PI3 kinase pathway in human glioma. In: Van Meir EG, ed. CNS Cancer: Models, Markers, Prognostic Factors, Targets and Therapeutic Approaches. 1st ed. New York: Humana Press (Springer); 2009:315-357.
22. Parsons DW, Jones S, Zhang X, et al. An integrated genomic analysis of human glioblastoma multiforme. Science. 2008; 321:1807-1812.
23. Zhao S, Lin Y, Xu W, et al. Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF1alpha. Science. 2009;324:261-265.
24. Belozerov VE, Van Meir EG. Inhibitors of hypoxia-inducible factor-1 signaling. Curr Opin Investig Drugs. 2006;7:1067-1076.
25. Dang L, White DW, Gross S, et al. Cancerassociated IDH1 mutations produce 2-hy droxyglutarate. Nature. 2009;462:739-744.
26. Misra A, Feuerstein BG. Discovery of genetic markers for brain tumors by comparative genomic hybridization. In: Van Meir EG. CNS Cancer: Models, Markers, Prognostic Factors, Targets and Therapeutic Approaches. 1st ed. New York: Humana Press (Springer); 2009.
27. Verhaak RGW, Hoadley KA, Purdom E, et al. An integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR and NF1. Cancer Cell. 2010;17:98-110.
28. Wen PY, Kesari S. Malignant gliomas in adults. N Engl J Med. 2008;359:492-507.
29. Gerstner ER, Batchelor TT. Clinical agents for the targeting of brain tumor vasculature. In: Van Meir EG, ed. CNS Cancer: Models, Markers, Prognostic Factors, Targets and Therapeutic Approaches. 1st ed. New York: Humana Press (Springer); 2009:731-728.
30. Zheng H, Ying H, Yan H, et al. p53 and Pten control neural and glioma stem/ progenitor cell renewal and differentiation. Nature. 2008;455:1129-1133.
31. Bellail AC, Mulligan P, Hao C. Targeting of TRAIL apoptotic pathways for glioblastoma therapies. In: Van Meir EG, ed. CNS Cancer: Models, Markers, Prognostic Factors, Targets and Therapeutic Approaches. 1st ed. New York: Humana Press (Springer); 2009:977-1010.
32. Li YC, Tzeng CC, Song JH, et al. Genomic alterations in human malignant glioma cells associate with the cell resistance to the combination treatment with tumor necrosis factor-related apoptosis-inducing ligand and chemotherapy. Clin Cancer Res. 2006;12:2716-2729.
33. Laver T, Nozell S, Benveniste EN. The NF-kB signaling pathway in GBMs: implications for apoptotic and inflammatory responses and exploitation for therapy. In: Van Meir EG, ed. CNS Cancer: Models, Markers, Prognostic Factors, Targets and TherapeuticApproaches.1sted.NewYork: Humana Press (Springer); 2009:1011-1036.
34. Hwang Y, Latha K, Gururaj A, Rojas M, Bogler O. Aberrant EGFR signaling in glioma. In: Van Meir EG, ed. CNS Cancer: Models, Markers, Prognostic Factors, Targets and Therapeutic Approaches. 1st ed. New York: Humana Press (Springer); 2009:441-459.
35. Thiessen B, Stewart C, Tsao M, et al. A phase I/II trial of GW572016 (lapatinib) in recurrent glioblastoma multiforme: clinical outcomes, pharmacokinetics and molecular correlation. Cancer Chemother Pharmacol. 2010;65:353-361.
36. Neyns B, Sadones J, Joosens E, et al. Stratified phase II trial of cetuximab in patients with recurrent high-grade glioma. Ann Oncol. 2009;20:1596-1603.
37. Mellinghoff IK, Wang MY, Vivanco I, et al. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med. 2005;353:2012-2024.
38. Haas-Kogan DA, Prados MD, Tihan T, et al. Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib. J Natl Cancer Inst. 2005;97:880-887.
39. van den Bent MJ, Brandes AA, Rampling R, et al. Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034. J Clin Oncol. 2009;27:1268-1274.
40. Assanah M, Lopez KA, Bruce JN, Canoll P. Modeling gliomas using PDGF-expressing retroviruses. In: Van Meir EG, ed. CNS Cancer: Models, Markers, Prognostic Factors, Targets and Therapeutic Approaches. 1st ed. New York: Humana Press (Springer); 2009:3-27.
41. Kilic T, Alberta JA, Zdunek PR, et al. Intracranial inhibition of platelet-derived growth factor-mediated glioblastoma cell growth by an orally active kinase inhibitor of the 2-phenylaminopyrimidine class. Cancer Res. 2000;60:5143-5150.
42. Wen PY, Yung WK, Lamborn KR, et al. Phase I/II study of imatinib mesylate for recurrentmalignantgliomas:NorthAmerican Brain Tumor Consortium Study 99-08. Clin Cancer Res. 2006;12:4899-4907.
43. Chang SM, Wen P, Cloughesy T, et al. Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme. Invest New Drugs. 2005;23:357-361.
44. Galanis E, Buckner JC, Maurer MJ, et al. Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study. J Clin Oncol. 2005;23:5294-5304.
45. Kreisl TN, Kim L, Moore K, et al. A phase I trial of enzastaurin in patients with recurrent gliomas. Clin Cancer Res. 2009;15: 3617-3623.
46. Cloughesy TF, Wen PY, Robins HI, et al. Phase II trial of tipifarnib in patients with recurrent malignant glioma either receiving or not receiving enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study. J Clin Oncol. 2006;24:3651-3656.
47. Galanis E, Jaeckle KA, Maurer MJ, et al. Phase II trial of vorinostat in recurrent glioblastoma multiforme: a north central cancer treatment group study. J Clin Oncol. 2009;27:2052-2058.
48. Atkinson JM, Gilbertson RJ, Rich JN. Brain cancer stem cells as targets of novel therapies. In: Van Meir EG, ed. CNS Cancer: Models, Markers, Prognostic Factors, Targets and Therapeutic Approaches. 1st ed. New York: Humana Press (Springer); 2009:1157-1175.
49. Stommel JM, Kimmelman AC, Ying H, et al. Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science. 2007;318:287-290.
50. Reardon DA, Desjardins A, Vredenburgh JJ, et al. Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma. J Neurooncol. 2010;96:219-230.
51. Robins HI, Wen PY, Chang SM, et al. Phase I study of erlotinib and CCI-779 (temsirolimus) for patients with recurrent malignant gliomas (NABTC 04-02). J Clin Oncol. 2007;25:2057.
52. Cloughesy TF, Yoshimoto K, Nghiemphu P, et al. Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma. PLoS Med. 2008;5:e8.
53. Jain RK, di Tomaso E, Duda DG, Loeffler JS, Sorensen AG, Batchelor TT. Angiogenesis in brain tumours. Nat Rev Neurosci. 2007;8:610-622.
54. Bergers G. Bone marrow-derived cells in GBM neovascularization. In: Van Meir EG, ed. CNS Cancer: Models, Markers, Prognostic Factors, Targets and Therapeutic Approaches. 1st ed. New York: Humana Press (Springer); 2009:749-773.
55. Schmidt NO, Westphal M, Hagel C, et al. Levels of vascular endothelial growth factor, hepatocyte growth factor/scatter factor and basic fibroblast growth factor in human gliomas and their relation to angio genesis. Int J Cancer. 1999;84:10-18.
56. Hu B, Guo P, Bar-Joseph I, et al. Neuropilin-1 promotes human glioma progression through potentiating the activity of the HGF/SF autocrine pathway. Oncogene. 2007;26:5577-5586.
57. Holash J, Maisonpierre PC, Compton D, et al. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science. 1999;284:1994-1998.
58. Oliner J, Min H, Leal J, et al. Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2. Cancer Cell. 2004;6:507-516.
59. Noguera-Troise I, Daly C, Papadopoulos NJ, et al. Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis. Nature. 2006;444:1032-1037.
60. Stark Vance V. Bevacizumab (Avastin) and CPT-11 (Camptosar) in the treatment of relapsed malignant glioma. Neurooncol. 2005;7:369.
61. Narayana A, Kelly P, Golfinos J, et al. Antiangiogenic therapy using bevacizumab in recurrent high-grade glioma: impact on local control and patient survival. J Neurosurg. 2009;110:173-180.
62. Nghiemphu PL, Liu W, Lee Y, et al. Bevacizumab and chemotherapy for recurrent glioblastoma: a single-institution experience. Neurology. 2009;72:1217-1222.
63. Poulsen HS, Grunnet K, Sorensen M, et al. Bevacizumab plus irinotecan in the treatment patients with progressive recurrent malignant brain tumours. Acta Oncol. 2009;48:52-58.
64. Zuniga RM, Torcuator R, Jain R, et al. Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumabplusirinotecan. JNeurooncol.2009; 91:329-336.
65. Guiu S, Taillibert S, Chinot O, et al. [Bevacizumab/irinotecan. An active treatment for recurrent high grade gliomas: preliminary results of an ANOCEF multicenter study]. Rev Neurol (Paris). 2008; 164:588-594.
66. Pope WB, Lai A, Nghiemphu P, Mischel P, Cloughesy TF. MRI in patients with highgrade gliomas treated with bevacizumab and chemotherapy. Neurology. 2006;66: 1258-1260.
67. Yung W, Albright R, Olson J, etal. AphaseII study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer. 2000;83:588-593.
68. Vredenburgh JJ, Desjardins A, Herndon JE 2nd, et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. Abstract. J Clin Oncol. 2007;25:4722-4729.
69. Yung WK, Prados MD, Yaya-Tur R, et al. Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. J Clin Oncol. 1999;17:2762-2771.
70. Friedman HS, Prados MD, Wen PY, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol. 2009;27:4733-4740.
71. United States Food and Drug Administration. FDA Briefing Document. Oncology Drug Advisory Committee Meeting. Washington, DC: United States Food and Drug Administration; 2009.
72. Kreisl TN, Kim L, Moore K, et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol. 2009;27:740-745.
73. Batchelor TT, Sorensen AG, di Tomaso E, et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell. 2007; 11:83-95.
74. Sorensen AG, Batchelor TT, Zhang WT, et al. A vascular normalization index as potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients. Cancer Res. 2009;69:5296-5300.
75. Guo P, Hu B, Gu W, et al. Platelet-derived growth factor-B enhances glioma angiogenesis by stimulating vascular endothelial growth factor expression in tumor endothelia and by promoting pericyte recruitment. Am J Pathol. 2003;162:1083-1093.
76. Avraamides CJ, Garmy-Susini B, Varner JA. Integrins in angiogenesis and lymphangiogenesis. Nat Rev Cancer. 2008;8: 604-617.
77. Stupp R, Goldbrunner R, Neyns B, et al. Mature results of a phase I/IIa trial of the integrininhibitorcilengitide(EMD121974) added to standard concomitant and adjuvant temozolomide and radiotherapy for newly diagnosed glioblastoma. Neurooncol. 2007;9:517.
78. Lamszus K, Kunkel P, Westphal M. Invasionaslimitationtoanti-angiogenicglioma therapy. Acta Neurochir Suppl. 2003;88: 169-177.
79. Erber R, Thurnher A, Katsen A, et al. Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms. FASEB J. 2004;18:338-340.
80. Bellail AC, Hunter SB, Brat DJ, Tan C, Van Meir EG. Microregional extracellular matrix heterogeneity in brain modulates glioma cell invasion. Int J Biochem Cell Biol. 2004;36:1046-1069.
81. Viapiano MS, Lawler SE. Glioma invasion: mechanisms and targeting opportunities. In: Van Meir EG, ed. CNS Cancer: Models, Markers, Prognostic Factors, Targets and TherapeuticApproaches.1sted.NewYork: Humana Press (Springer); 2009:1219-1252.
82. Walker PR, Prins RM, Dietrich P-Y, Liau LM. Harnessing T-cell immunity to target brain tumors. In: Van Meir EG, ed. CNS Cancer: Models, Markers, Prognostic Factors, Targets and Therapeutic Approaches. 1st ed. New York: Humana Press (Springer); 2009:1165-1217.
83. Desbaillets I, Diserens AC, Tribolet N, Hamou MF, Van Meir EG. Upregulation of interleukin 8 by oxygen-deprived cells in glioblastoma suggests a role in leukocyte activation, chemotaxis, and angiogenesis. J Exp Med. 1997;186:1201-1212.
84. Ayriss JE, Kuan C-T, Boulton ST, Reardon DA, Bigner DD. Molecular targets for antibody-mediated immunotherapy of malignant glioma. In: Van Meir EG, ed. CNS Cancer: Models, Markers, Prognostic Factors, Targets and Therapeutic Approaches. 1st ed. New York: Humana Press (Springer); 2009:865-898.
85. Stewart LA. Chemotherapy in adult highgrade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet. 2002; 359:1011-1018.
86. Rivera AL, Pelloski CE, Gilbert MR, Colman H, De La Cruz C, Sulman EP, Bekele BN, Aldape KD. MGMT promoter methylation is predictive of response to radiotherapy and prognostic in the absence of adjuvant alkylating chemotherapy for glioblastoma. Neuro Oncol. 2010;12:116-121.
87. Tolcher AW, Gerson SL, Denis L, et al. Marked inactivation of O6-alkylguanine- DNA alkyltransferase activity with protracted temozolomide schedules. Br J Cancer. 2003;88:1004-1011.
88. Broniscer A, Gururangan S, MacDonald TJ, et al. Phase I trial of single-dose temozolomide and continuous administration of O6-benzylguanine in children with brain tumors: a pediatric brain tumor consortium report. Clin Cancer Res. 2007; 13:6712-6718.
89. Donawho CK, Luo Y, Penning TD, et al. ABT-888, an orally active poly(ADPribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models. Clin Cancer Res. 2007;13: 2728-2737.
90. Khwaja FW, Van Meir EG. Proteomic discovery of biomarkers in the cerebrospinal fluid of brain tumor patients. In: Van Meir EG, ed. CNS Cancer: Models, Markers, Prognostic Factors, Targets and Therapeutic Approaches. 1st ed. New York: Humana Press (Springer); 2009:577-614.
91. Khwaja FW, Reed MS, Olson JJ, et al. Proteomic identification of biomarkers in the cerebrospinal fluid (CSF) of astrocytoma patients. J Proteome Res. 2007;6:559-570.
92. Van Meir EG, Sawamura Y, Diserens A-C, Hamou M-F, de Tribolet N. Human glioblastoma cells release interleukin 6 in vivo and in vitro. Cancer Res. 1990;50:6683-6688.
93. Van Meir E, Ceska M, Effenberger F, et al. Interleukin-8 is produced in neoplastic and infectious diseases of the human central nervous system. Cancer Res. 1992; 52:4297-4305.
94. Kuratsu J, Yoshizato K, Yoshimura T, Leonard EJ, Takeshima H, Ushio Y. Quantitative study of monocyte chemoattractant protein-1 (MCP-1) in cerebrospinal fluid and cyst fluid from patients with malignant glioma. J Natl Cancer Inst. 1993;85:1836-1839.
95. Frei K, Piani D, Malipiero UV, Van Meir EG, de Tribolet N, Fontana A. Granulocyte-macrophage colony-stimulating factor (GM-CSF) production by glioblastoma cells: despite the presence of inducing signals GM-CSF is not expressed in vivo. J Immunol. 1992;148:3140-3146.
96. Desbaillets I, Tada M, de Tribolet N, Diserens AC, Hamou MF, Van Meir EG. Human astrocytomas and glioblastomas express monocyte chemoattractant protein-1 (MCP-1) in vivo and in vitro. Int J Cancer. 1994;58:240-247.
97. Khwaja F, Duke-Cohan JS, Brat DJ, Van Meir EG. Attractin is elevated in the cerebrospinal fluid (CSF) of patients with malignant astrocytoma and mediates glioma cell migration. Clin Cancer Res. 2006;12:6331-6336.
98. Cappabianca P, Cinalli G, Gangemi M, et al. Application of neuroendoscopy to intraventricular lesions. Neurosurgery. 2008; 62(suppl 2):575-597.
99. Souweidane MM, Luther N. Endoscopic resection of solid intraventricular brain tumors. J Neurosurg. 2006;105:271-278.
100. Greenlee JD, Teo C, Ghahreman A, Kwok B. Purely endoscopic resection of colloid cysts. Neurosurgery. 2008;62:51-55.
101. Hopf NJ, Grunert P, Fries G, Resch KD, PerneczkyA.Endoscopicthirdventriculostomy: outcome analysis of 100 consecutive procedures. Neurosurgery. 1999;44: 795-804.
102. Lekovic GP, Gonzalez LF, Feiz-Erfan I, Rekate HL. Endoscopic resection of hypothalamic hamartoma using a novel variable aspiration tissue resector. Neurosurgery. 2006; 58:ONS166-ONS169.
103. Sanai N, Berger MS. Glioma extent of resection and its impact on patient outcome. Neurosurgery. 2008;62:753-764.
104. Vuorinen V, Hinkka S, Farkkila M, Jaaskelainen J. Debulking or biopsy of malignant gliomainelderlypeople-arandomisedstudy. ActaNeurochir(Wien).2003;145:5-10.
105. Tonn JC, Stummer W. Fluorescenceguided resection of malignant gliomas using 5-aminolevulinic acid: practical use, risks,andpitfalls. ClinNeurosurg.2008;55: 20-26.
106. Stummer W, Pichlmeier U, Meinel T, Wiestler OD, Zanella F, Reulen HJ. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. Lancet Oncol. 2006;7: 392-401.
107. Hadjipanayis CG, Bonder MJ, Balakrishnan S, Wang X, Mao H, Hadjipanayis GC. Metallic iron nanoparticles for MRI contrast enhancement and local hyperthermia. Small. 2008;4:1925-1929.
108. Walker MD, Strike TA, Sheline GE. An analysis of dose-effect relationship in the radiotherapy of malignant gliomas. Int J Radiat Oncol Biol Phys. 1979;5:1725-1731.
109. Chan MF, Schupak K, Burman C, Chui CS, Ling CC. Comparison of intensity-modulated radiotherapy with three-dimensional conformal radiation therapy planning for glioblastoma multiforme. Med Dosim. 2003;28:261-265.
110. McDonald MW, Shu HG, Curran WJ, Crocker IR. Pattern of failure after limited margin radiotherapy and temozolomide in glioblastoma. Int J Radiat Oncol Biol Phys. 2010; In Press.
111. Lawson JD, Fox T, Elder E, et al. Early clinical experience with kilovoltage imageguided radiation therapy for interfraction motionmanagement.MedDosim.2008;33: 268-274.
112. Tsao MN, Mehta MP, Whelan TJ, et al. The American Society for Therapeutic Radiology and Oncology (ASTRO) evidencebased review of the role of radiosurgery for malignant glioma. Int J Radiat Oncol Biol Phys. 2005;63:47-55.
113. Souhami L, Seiferheld W, Brachman D, et al. Randomized comparison of stereotactic radiosurgery followed by conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma multiforme: report of Radiation Therapy Oncology Group 93-05 protocol. Int J Radiat Oncol Biol Phys. 2004;60:853-860.
114. Larson DA, Prados M, Lamborn KR, et al. Phase II study of high central dose Gamma Knife radiosurgery and marimastat in patients with recurrent malignant glioma. Int J Radiat Oncol Biol Phys. 2002;54:1397-1404.
115. Combs SE, Widmer V, Thilmann C, Hof H, Debus J, Schulz-Ertner D. Stereotactic radiosurgery (SRS): treatment option for recurrent glioblastoma multiforme (GBM). Cancer. 2005;104:2168-2173.
116. Adler JR Jr, Chang SD, Murphy MJ, Doty J, Geis P, Hancock SL. The Cyberknife: a frameless robotic system for radiosurgery. Stereotact Funct Neurosurg. 1997; 69:124-128.
117. Meeks SL, Tome WA, Willoughby TR, et al. Optically guided patient positioning techniques. Semin Radiat Oncol. 2005;15: 192-201.
118. Wurm RE, Erbel S, Schwenkert I, et al. Novalis frameless image-guided noninvasive radiosurgery: initial experience. Neurosurgery. 2008;62(suppl 5):A11-A17.
119. Fitzek MM, Thornton AF, Rabinov JD, et al. Accelerated fractionated proton/photon irradiation to 90 cobalt gray equivalent for glioblastoma multiforme: results of a phase II prospective trial. J Neurosurg. 1999;91:251-260.
120. Chan JL, Lee SW, Fraass BA, et al. Survival and failure patterns of high-grade gliomas after three-dimensional conformal radiotherapy. J Clin Oncol. 2002;20:1635-1642.
121. Nelson DF, Diener-West M, Weinstein AS, et al. A randomized comparison of misonidazole sensitized radiotherapy plus BCNU and radiotherapy plus BCNU for treatment of malignant glioma after surgery: final report of an RTOG study. Int J Radiat Oncol Biol Phys. 1986;12:1793-1800.
122. Prados MD, Seiferheld W, Sandler HM, et al. Phase III randomized study of radiotherapy plus procarbazine, lomustine, and vincristine with or without BUdR for treatment of anaplastic astrocytoma: final report of RTOG 9404. Int J Radiat Oncol Biol Phys. 2004;58:1147-1152.
123. van Nifterik KA, van den Berg J, Stalpers LJ, et al. Differential radiosensitizing potential of temozolomide in MGMT promoter methylated glioblastoma multiforme cell lines. Int J Radiat Oncol Biol Phys. 2007;69:1246-1253.
124. O'Rourke DM, Kao GD, Singh N, et al. Conversion of a radioresistant phenotype to a more sensitive one by disabling erbB receptor signaling in human cancer cells. Proc Natl Acad Sc i U S A. 1998;95:10842-10847.
125. Li B, Yuan M, Kim IA, Chang CM, Bernhard EJ, Shu HK. Mutantepidermalgrowth factor receptor displays increased signaling through the phosphatidylinositol-3 kinase/AKT pathway and promotes radioresistance in cells of astrocytic origin. Oncogene. 2004;23:4594-4602.
126. Gerstner ER, Sorensen AG, Jain RK, Batchelor TT. Advances in neuroimaging techniques for the evaluation of tumor growth, vascular permeability, and angiogenesis in gliomas. Curr Opin Neurol. 2008;21:728-735.
127. Ogawa T, Shishido F, Kanno I, et al. Cerebral glioma: evaluation with methionine PET. Radiology. 1993;186:45-53.
128. Shoup TM, Olson J, Hoffman JM, et al. Synthesis and evaluation of [18F]1-amino- 3-fluorocyclobutane-1-carboxylic acid to image brain tumors. J Nucl Med. 1999;40: 331-338.
129. Chen W, Cloughesy T, Kamdar N, et al. Imaging proliferation in brain tumors with 18F-FLT PET: comparison with 18F- FDG. J Nucl Med. 2005;46:945-952.
130. Cher LM, Murone C, Lawrentschuk N, et al. Correlation of hypoxic cell fraction and angiogenesis with glucose metabolic rate in gliomas using 18F-fluoromisonidazole, 18F-FDG PET, and immunohistochemical studies. J Nucl Med. 2006;47:410-418.
131. Martin M. Laser accelerated radiotherapy: is it on its way to the clinic? J Natl Cancer Inst. 2009;101:450-451.
132. Weaver KD, Pierce L, Herman JG, Grossman SA. Real-time polymerase chain reaction technique determines absolute copy number of plasma methylated MGMT gene promoter copies in newly diagnosed malignant glioma patients. J Clin Oncol. 2008;26: Abstract 22073.